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Summary
Background Self-directed and internet-based care are key elements of eHealth agendas. We developed a complex 
online clinical and public health intervention, the eSexual Health Clinic (eSHC), in which patients with genital 
chlamydia are diagnosed and medically managed via an automated online clinical consultation, leading to antibiotic 
collection from a pharmacy. Partner notification, health promotion, and capture of surveillance data are integral 
aspects of the eSHC. We aimed to assess the safety and feasibility of the eSHC as an alternative to routine care in non-
randomised, exploratory proof-of-concept studies. 
Methods Participants were untreated patients with chlamydia from genitourinary medicine clinics, untreated patients 
with chlamydia from six areas in England in the National Chlamydia Screening Programme’s (NCSP) online postal 
testing service, or patients without chlamydia tested in the same six NCSP areas. All participants were aged 16 years 
or older. The primary outcome was the proportion of patients with chlamydia who consented to the online chlamydia 
pathway who then received appropriate clinical management either exclusively through online treatment or via a 
combination of online management and face-to-face care. We captured adverse treatment outcomes.
Findings Between July 21, 2014, and March 13, 2015, 2340 people used the eSHC. Of 197 eligible patients from 
genitourinary medicine clinics, 161 accessed results online. Of the 116 who consented to be included in the study, 
112 (97%, 95% CI 91–99) received treatment, and 74 of those were treated exclusively online. Of the 146 eligible NCSP 
patients, 134 accessed their results online, and 105 consented to be included. 93 (89%, 95% CI 81–94) received 
treatment, and 60 were treated exclusively online. In both groups, median time to collection of treatment was within 
1 day of receiving their diagnosis. 1776 (89%) of 1936 NCSP patients without chlamydia accessed results online. No 
adverse events were recorded.
Interpretation The eSHC is safe and feasible for management of patients with chlamydia, with preliminary evidence 
of similar treatment outcomes to those in traditional services. This innovative model could help to address growing 
clinical and public health needs. A definitive trial is needed to assess the efficacy, cost-effectiveness, and public health 
impact of this intervention.
Funding UK Clinical Research Collaboration.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Well evidenced, high-quality interventions need to be 
delivered in innovative and efficient ways to meet the 
growing health needs of the population. Digital 
technologies provide opportunities for alternative modes 
of health-care delivery and for public health inter-
ventions—so-called eHealth. UK health strategy strongly 
supports development of eHealth and self-managed care, 
with the aim of increasing both the quality and 
accessibility of health care while reducing total health 
expenditure.1,2 However, eHealth provision for medical 
management is mostly limited to monitoring or support 
for people with chronic disorders that have been 
diagnosed in traditional care settings.3 Yet the potential 
impact of eHealth extends beyond individual patients. In 
infectious diseases, for example, eHealth inter ventions 
could be used to facilitate risk-reduction strategies, 
provide clinical management of cases, and interrupt 
transmission in the population.
Chlamydia trachomatis is the most commonly reported 
bacterial sexually transmitted infection (STI) in the UK 
(220 000 reported cases per year in England).4 Chlamydia 
mainly affects people aged 16–24 years,4 an age group 
who use digital technology avidly.5 Untreated and repeat 
infections can result in serious and costly reproductive 
health sequelae.6 The National Chlamydia Screening 
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Programme (NCSP) was established in England in 2003, 
and offers opportunistic screening to young sexually 
active people. Around half of all cases of chlamydia are 
managed within genitourinary medicine (GUM) or 
sexual health services, which offer open-access specialist 
care without the need for referral from a general 
practitioner. In England, data for new diagnoses are 
submitted to Public Health England by the service 
provider or laboratory for surveillance purposes.
Recommended first-line treatments include a single 
dose of oral azithromycin.7 Uncomplicated chlamydia 
could therefore be an appropriate candidate for an 
eHealth intervention. However, a systematic review8 of 
con temporary mobile applications for people seeking 
information about STIs did not identify any apps that 
provided a diagnosis and clinical care online.
As part of the Electronic Self-Testing Instruments for 
Sexually Transmitted Infection Consortium,2 we 
developed an eSexual Health Clinic (eSHC) system for 
management, prevention, and control of STIs. To our 
knowledge, this system is the first of its kind within the 
UK’s National Health Service (NHS) and internationally. 
It meets legal and regulatory requirements, and national 
standards for medical management7,9,10 and data 
protection.11,12
Through sexual health promotion, treatment of cases, 
and partner notification, the eSHC system could improve 
STI control and reduce incidence of Chlamydia 
trachomatis. Targeting young people should produce the 
greatest impact, because they engage with new tech-
nologies, have the highest STI rates, might not engage 
with health services,13 and expect information to be 
delivered rapidly and in a way that addresses individual 
need. In this Article, we describe this complex 
intervention and report on exploratory studies to assess 
safety and feasibility in GUM services and within the 
NCSP, and public health potential.
Methods
Background work and the eSHC
We followed the UK Medical Research Council 
framework for the development of complex interventions, 
and did extensive multidisciplinary, mixed-methods pre-
liminary work before our study.3,8,14–19 This work included 
in-depth scrutiny of the legal and regulatory requirements 
of online care, a review of sexual health apps,8 addressing 
issues in linking online pathways to surveillance,19 and 
qualitative interviews with young people exploring 
acceptability14 and user-centred design and interface 
testing.17 We developed the eClinical Care Pathway 
Framework, a novel structure for the creation of online 
complex clinical care pathways, which we applied to 
develop the innovative eSHC system.16
The eSHC system (figure 1) consists of a web application 
with different portals for patients, results administrators, 
health advisers, and researchers. Care is self-directed and 
achievable entirely remotely from traditional medical 
services. The patient interface includes a results service, 
access to health promotion, and the online chlamydia 
pathway. After patients provide online consent, those who 
test positive for chlamydia engage in an automated online 
consultation (a clinical decision-making tool), which 
adheres to national guidance for chlamydia management7 
and includes assessment of symptoms, past medical 
Research in context
Evidence before this study
We did several searches of published work and grey literature to 
inform this study, including on individual components of the 
pathway (results service, clinical consultation, partner 
notification, treatment and prescribing). Within contemporary 
sexual health services in the UK, some digital technologies, such 
as text messaging of test results for sexually transmitted 
infections (STIs) and postal self-sampling, are well established. 
However, face-to-face or telephone contact with a clinician is still 
required for assessment and treatment of people with diagnosed 
infections. In a 2014 study based in California, investigators 
explored the acceptability and feasibility of an online system for 
integrated STI care in women. However, only eight participants 
were diagnosed with an STI and clinicians had to fax 
individualised prescriptions to a pharmacy. A systematic review of 
contemporary mobile applications for people seeking 
information about STIs did not identify any apps that provided 
clinical care online. Some National Chlamydia Screening 
Programme areas now offer an online results service, a feature 
that was not available at the time of our study and has not been 
formally assessed elsewhere.
Added value of this study
We have shown the safety and feasibility of a complex online 
clinical and public health intervention integrated within 
traditional sexual health services, the eSexual Health Clinic 
(eSHC) system for management, prevention, and control of 
sexually transmitted infections, and preliminary evidence of 
effectiveness and public health potential. Our results show 
that the eSHC can be integrated with existing genitourinary 
medicine clinical care pathways and internet-based 
self-sampling services, to provide management of both 
patients with uncomplicated chlamydia and those who test 
negative, wholly remotely from traditional services.
Implications of all the available evidence
The eSHC offers a novel approach to provision of care by allowing 
management of a subsection of people with uncomplicated 
chlamydial infection with an automated online clinical care 
pathway—a major departure from any method of care delivery in 
current practice. This rigorously developed, online, remote, 
automated approach to clinical care and public health provision 
could be applicable to many medical conditions.
For more on the Electronic 
Self-Testing Instruments for 
Sexually Transmitted 
Infection Consortium see 
http://www.esti2.org.uk
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history, medication and allergy history, sexual history, and 
a risk assessment. It encompasses all clinical and public 
health surveillance data routinely collected in traditional 
services.
If medically appropriate, the patient nominates one of 
30 participating community pharmacies from which to 
collect antibiotic treatment, which is authorised via 
automated email sent via secure NHS email. Sexual 
partners of people with chlamydia are recommended to 
receive treatment (partner notification).7 Index patients 
can request a unique access code for their sexual partners 
to access care via the online chlamydia pathway. Patients 
whom the clinical algorithm predicts are inappropriate for 
online care (eg, those with symptoms, allergies, or drug 
interactions) are directed to call the clinical helpline. The 
helpline, which was accessible from 0900 h to 1700 h on 
weekdays, was staffed by research health advisers (ie, 
employees of sexual health clinics who are responsible for 
partner notification and sexual health promotion, among 
other roles), who were able to facilitate face-to-face care.10
Study participants and settings
To assess the safety, feasibility, and public health 
potential of the eSHC, we did non-randomised proof-
of-concept exploratory studies in three different groups 
of participants across Greater London: untreated 
patients with chlamydia from two GUM clinics serving 
deprived, ethnically diverse local populations and a 
commuter population; patients with chlamydia who 
were tested through the Checkurself NCSP online 
service—which enables people to request a self-
sampling kit and post a urine (men) or vulvo-vaginal 
swab sample (women) to a laboratory for testing; 
results are received via text message, letter, or phone 
call, and infections are managed via traditional 
services—in six NCSP areas in South London, where 
the prevalence of chlamydia infection is high; and 
patients in the same six areas who used the NCSP’s 
Checkurself online service but tested negative for 
chlamydia. In GUM clinics, we hypothesised that the 
eSHC could be used to complement face-to-face 
specialist care by managing uncomplicated cases. For 
NCSP Checkurself users, we assessed the feasibility of 
the eSHC in a group of potential users who have 
already engaged with online care (if successful, scale-
up within the NCSP would be possible). Inclusion of 
people who tested negative enabled assessment of 
uptake and timing of use of the eSHC to access results 
and health promotion. Ethical approval was granted by 
Brighton & Sussex (NHS) Research Ethics Committee.
Figure 1: eSHC system and online chlamydia pathway
The eSHC system is an online sexual health service. The online chlamydia pathway sits within the eSHC and encompasses the various pathways that patients can 
follow after receiving a text allowing them to access their results up to the 2-week follow-up with a health adviser. People who did not access their results within 
7 days, and patients testing positive for chlamydia who did not consent to take part in our study within 7 days, were passed back to the original testing site to be 
managed via traditional care pathways. eSHC=eSexual Health Clinic.
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Eligible patients were aged 16 years or older (or aged 
16–24 years in the NCSP Checkurself group) and able to 
read and understand English. Exclusion criteria were 
coexisting STIs, having already received presumptive 
treatment for chlamydia, and extragenital chlamydia. All 
eligible patients who provided consent were managed by 
the eSHC. The eSHC sent an automated text message to 
eligible patients, informing them that their test results 
were available and inviting them to follow a link to a 
password-protected web app, designed specifically for the 
study, to access their result (online results service), and 
then online treatment. Chlamydia-negative users received 
an automated text message containing a link to the online 
results service followed by health-promotion advice and a 
short acceptability survey. Research health advisers 
telephoned all patients 2 weeks after diagnosis for clinical 
follow-up, ascertainment of partner-notification outcomes, 
and collection of research data. People who declined to 
participate in the study were managed according to routine 
clinical practice.
Outcomes
The primary outcome was the proportion of patients 
with chlamydia who consented to the online chlamydia 
pathway (index patients) who then received appropriate 
clinical management7,10 either exclusively through online 
managment or via a combination of online management 
and face-to-face care. We collected demo graphic data and 
outcomes only for patients who consented to the study. 
Quantitative secondary outcomes were the proportion of 
index patients who received antibiotic treatment solely 
online, time from diagnosis to appropriate treatment in 
index patients, and proportion of sex partners treated 
online. We also captured adverse treatment outcomes.
Treatment outcomes were captured by the eSHC 
system when the community pharmacist who provided 
the azithromycin to the patient confirmed electronically 
that treatment had been collected (all pharmacists at 
included pharmacies had access to the secure email). 
Treatment outcomes for patients who left the online 
chlamydia pathway at any stage were ascertained at the 
2-week follow-up telephone assessment and from clinical 
records from participating clinics and NCSP Checkurself 
services. Patients uncontactable at telephone follow-up 
and for whom no clinical record of treatment was 
available were assumed to be untreated.
Statistical analyses
We calculated the required sample size on the basis of 
the primary outcome. We aimed to demonstrate non-
inferiority of the eSHC—ie, that treatment outcomes for 
index patients are better or only slightly worse than 
current routine care—while assuming that the online 
pathway would lead to a small improvement in 
outcomes. We calculated sample sizes separately for the 
exploratory studies in GUM clinics and NCSP 
Checkurself services, because the proportion of patients 
who receive appropriate treatment in routine care differs 
substantially between the two (~98% in GUM clinics vs 
~88% in the NCSP).20 For GUM clinics, assuming that 
the true proportion of index patients receiving 
appropriate treatment would be slightly higher in the 
eSHC (ie, 99%) than that in current care, then 
121 patients would provide 80% power to show that the 
proportion is greater than 94% (ie, to show non-
inferiority assuming a non-inferiority margin of 4%). 
Assuming that the proportion of index patients treated 
in the eSHC via the NSCP would be slightly higher (ie, 
90%) than that in current care, 108 patients would be 
needed to show that the proportion is greater than 
80%—ie, to show non-inferiority, assuming a non-
inferiority margin of 8%. In the sample size calculations, 
we assumed one-sided statistical tests and a 
2·5% significance level. We specified a single sample 
and prevalence of 99% in GUM clinics and 90% in the 
NCSP as the alternative hypothesis, and 94% in GUM 
clinics and 80% in the NCSP as the null hypothesis. A 
smaller non-inferiority margin was selected for GUM 
Figure 2: Flow diagram of study participants
GUM=genitourinary medicine. NCSP=National Chlamydia Screening Programme.
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clinics than for the NCSP, because in GUM clinics the 
treatment rate is higher, and therefore any reduction in 
the rate translates to a higher proportionate increase in 
the numbers untreated.
The proportion of index patients achieving the primary 
outcome is reported for each setting with an exact binomial 
95% CI. These two-sided 95% CIs provide the basis of 
assessing non-inferiority in each setting, corresponding to 
one-sided tests at a 2·5% significance level. We plotted 
cumulative percentage of time to treatment. All analyses 
were done in Stata (version 14.1).
Role of the funding source
The study sponsor had no role in study design; data 
collection, analysis, or interpretation; or the writing of 
the Article. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between July 21, 2014, and March 13, 2015, 2340 people 
used the eSHC (figure 2). 197 patients with chlamydia 
(70 men and 127 women) were recruited from GUM 
clinics and 146 (66 men and 80 women) from the NCSP 
Checkurself service. 161 (82%; 95% CI 76–87) GUM 
patients accessed the online results service within 7 days 
of receiving the text message, of whom 116 (72%) 
consented to be included in our study. 134 (92%; 95% CI 
87–96) NCSP patients accessed the online results service 
within 7 days, of whom 105 (78%) consented to inclusion. 
GUM clinics NCSP Checkurself
Total (n=116) Men (n=42) Women (n=74) Total (n=105) Men (n=45) Women (n=60)
Median age, years (IQR) 25 (23–28) 26 (23–29) 25 (22–28) 22 (20–23) 22 (20–24) 22 (20–23)
Ethnicity
n 104 37 67 94 42 52
White British 37 (36%) 15 (41%) 22 (33%) 67 (71%) 28 (67%) 39 (75%)
White other 29 (28%) 8 (22%) 21 (31%) 5 (5%) 3 (7%) 2 (4%)
Black 17 (16%) 5 (14%) 12 (18%) 12 (13%) 6 (14%) 6 (12%)
Asian, mixed race, or other 21 (20%) 9 (24%) 12 (18%) 10 (11%) 5 (12%) 5 (10%)
Number of sexual partners in past 6 months
n 83 36 47 71 37 34
0–1 20 (24%) 7 (19%) 13 (28%) 21 (30%) 11 (30%) 10 (29%)
2–5 54 (65%) 21 (58%) 33 (70%) 42 (59%) 20 (54%) 22 (65%)
≥6 9 (11%) 8 (22%) 1 (2%) 8 (11%) 6 (16%) 2 (6%)
Previous chlamydia
n 84 37 47 72 38 34
Yes 25 (30%) 8 (22%) 17 (36%) 27 (38%) 7 (18%) 20 (59%)
No 59 (70%) 29 (78%) 30 (64%) 45 (63%) 31 (82%) 14 (41%)
Sexual partner from outside UK or Ireland*
n 84 37 47 72 38 34
Yes 34 (40%) 14 (38%) 20 (43%) 15 (21%) 12 (32%) 3 (9%)
No 50 (60%) 23 (62%) 27 (57%) 57 (79%) 26 (68%) 31 (91%)
Same-sex partner in past 6 months*†
n 82 35 47 71 37 34
Yes 1 (1·0%) 1 (3%) 0 3 (4%) 3 (8%) 0
No 81 (99·0%) 34 (97%) 47 (100%) 68 (96%) 34 (92%) 34 (100%)
Ever had sex with a man*†‡
n ·· 34 ·· ·· 34 ··
Yes ·· 0 ·· ·· 1 (3·0%) ··
No ·· 34 (100%) ·· ·· 33 (97·1%) ··
Ever paid for, or been paid for, sex
n 83 36 47 71 36 35
Yes 2 (2%) 2 (6%) 0 3 (4%) 3 (8%) 0
No 81 (98%) 34 (94%) 47 (100%) 68 (96%) 33 (92%) 35 (100%)
Data are n (%) unless otherwise specified. Information is missing in this table because data were missing or patients left the online pathway. No patients reported 
injecting-drug use. GUM=genitourinary medicine. NCSP=National Chlamydia Screening Programme. *These questions are routinely collected markers of risk for sexually 
transmitted infections. †Patients were initially asked if they had had sex with a partner or partners of the opposite sex, same sex, or both sexes in the preceding 6 months. 
‡Only men who reported having sex only with women in the past 6 months were asked this question.
Table 1: Characteristics of patients with chlamydia who consented to online management
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Further results in patients with chlamydia are limited to 
those who consented.
Participant characteristics are shown in table 1. 
36 (86%) of 42 men and 46 (62%) of 74 women recruited 
from GUM clinics completed the online consultation 
and had treatment authorised. Of these patients, 32 men 
(89%) and 42 women (91%) collected their treatment 
from their chosen pharmacy. Of the 34 GUM clinic 
patients who left the online pathway, 26 (73%; three men 
and 23 women) reported symptoms and needed assess-
ment as to whether examination, further investigations, 
and treatment for complicated chlamydia were indicated. 
30 of these patients subsequently received treatment; 
four were lost to follow-up.
112 (97%; 95% CI 91–99) of the 116 GUM patients were 
treated either via the eSHC or through traditional 
services (table 2). 74 patients (64%) completed the online 
consultation and collected their treatment at their chosen 
pharmacy, of whom 56 (76%) did not contact the clinical 
helpline (table 2). 32 (43%) of the 74 patients who 
completed the online consultation accessed their 
treatment on the same day as receiving the text message 
(shortest time to collection of treatment was 32 minutes; 
figure 3). By the end of the following day, 56 patients 
(76%) had accessed their treatment (figure 3).
83 (72%) of 116 GUM patients completed the online 
consultation at least as far as the section requiring 
reporting of sexual partner numbers (one subsequently 
left the online pathway); they reported 253 sexual 
partners within the past 6 months. 15 sexual partners 
accessed the eSHC—12 collected their treatment from 
their chosen pharmacy, two were treated elsewhere, and 
one was lost to follow-up.
34 (29%) of the 116 GUM patients accessed health-
promotion resources (18 [16%] logged back in to do so), 
of whom 11 (32%) followed links to access further 
information.
37 (82%) of 45 men and 32 (53%) of 60 women from 
the NCSP completed the online consultation and had 
treatment authorised (figure 2). 33 (89%) of these men 
and 27 (84%) of these women collected treatment from 
their chosen pharmacy. Of the 36 patients who left the 
online pathway, 25 (69%; six men and 19 women) 
reported symptoms, 27 (75%) received treatment, and 
nine (25%) were lost to follow-up.
93 (89%; 95% CI 81–94) patients from the NCSP 
Checkurself service were treated, and 60 patients (57%) 
were treated solely online and collected their treatment 
(table 2). 50 (83%) of these online-only patients accessed 
treatment completely remotely without needing to use 
the clinical helpline. 27 (45%) online-only patients 
accessed their treatment on the day that they received 
their results, and 40 (67%) accessed treatment by the end 
of the following day (figure 3). 71 patients from the NCSP 
Checkurself service reported 199 sexual partners online. 
13 sexual partners accessed the eSHC, of whom 
seven collected treatment from their chosen pharmacy, 
two received treatment elsewhere, and four had unknown 
treatment outcomes.
32 (30%) of the 105 patients from the NCSP Checkurself 
service accessed health-promotion resources (17 [16%] 
logged back in to do so), of whom nine (28%) followed 
links to access further information.
Patients treated Patients treated solely online*
Total Without helpline contact
Genitourinary medicine clinics
Total (n=116) 112 (97%, 95% CI 91–99) 74 (64%, 95% CI 55–73%) 56 (48%, 95% CI 39–58)
Men (n=42) 41 (98%) 32 (76%) 23 (55%) 
Women (n=74) 71 (96%) 42 (57%) 33 (45%)
National Chlamydia Screening Programme
Total (n=105) 93 (89%, 95% CI 81–94) 60 (57%, 95% CI 48–67%) 50 (48%, 95% CI 38–58)
Men (n=45) 41 (91%) 33 (73%) 29 (64%)
Women (n=60) 52 (87%) 27 (45%) 21 (35)
Data are n (%). *Patients who managed all their care online and collected treatment from community pharmacy. 
Table 2: Treatment outcomes in index patients from genitourinary medicine clinics and the National 
Chlamydia Screening Programme Checkurself service
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Figure 3: Time to treatment for patients from genitourinary medicine clinics (A) and the National Chlamydia 
Screening Programme (B) accessing treatment via the online chlamydia pathway
n=74 for (A) and 60 for (B). Range for (A) was 0–14 days and for (B) was 0–24 days. Median time to treatment was 1 day 
(IQR 0–1) for (A) and 1 day (IQR 0–4) for (B).
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No patients in either group who reported contraindicated 
health conditions, interacting drug therapies, or relevant 
allergies were prescribed azithromycin via the online 
pathway. No serious adverse reactions to azithromycin 
were reported.
1997 users tested negative for genital chlamydia, 
1776 (89%) of whom accessed their test results within 
7 days via the online results service. 433 (24%) of those 
who accessed their results online also accessed health-
promotion resources, of whom 142 (33%) followed links 
to access further information.
Discussion
We have developed, implemented, and assessed an online 
system for management, prevention, and control of 
sexually transmitted infections, and demonstrated its 
feasibility and safety in exploratory studies. Each study 
provides information that can be used to refine the 
intervention, and shows how the intervention can be used 
in different settings. The eSHC is unique in that it 
integrates online results access with an automated clinical 
consultation, authorisation of antibiotics, partner notifi-
cation, routing of patients into traditional care (when 
appropriate), and potential linkage to surveillance (panel).
Relative to our prespecified margins, we showed non-
inferiority of the proportion treated by the eSHC relative 
to current care for NCSP patients but not for GUM 
patients. Although our outcomes are encouraging, they 
should be viewed as preliminary evidence of effectiveness. 
The target sample size for the primary outcomes in both 
GUM clinics and the NCSP was narrowly missed, and 
the small numbers prohibited sub-analyses. Furthermore, 
because GUM clinics and the NCSP have different 
sociodemographic, behavioural, and clinical mixes, and 
different proportions of patients receiving treatment 
under routine care, we do not compare characteristics or 
outcomes of the two patient populations.
Around three-quarters of eligible people chose to access 
the online chlamydia pathway and roughly 60% of 
patients managed their care completely remotely. Others 
moved effectively between online, telephone, and clinic-
based care. Almost a quarter of patients contacted the 
clinical helpline at some point, suggesting that provision 
of telephone support is important. Those who were 
directed off the online pathway for clinical reasons were 
for the most part successfully managed in traditional 
settings. More women than men reported symptoms 
suggestive of complicated infection, in line with clinical 
expect ations,6 which explains the higher proportion of 
women routed into face-to-face clinical assessment. A few 
patients did not collect their treatment from the pharmacy, 
but most of them accessed treatment elsewhere.
The online consultation facilitated safe prescribing. 
Integral to the eSHC is a sophisticated triage system, 
which allows individuals who need to be seen face-to-face 
to be fast-tracked to a sexual health clinic or other 
services.
People with chlamydia require prompt treatment10 (at 
the time of our studies, the NCSP aimed to treat 95% of 
patients within 6 weeks21), both to reduce development 
of sequelae and to limit the infectious period, thereby 
reducing opportunities for onward transmission of 
infection. The swift treatment afforded online through 
the eSHC could confer important personal and public 
health gains, especially in people who report high-risk 
sexual behaviours, such as some of the participants in 
our study. Similarly, the eSHC  could be advantageous 
for people requesting internet-based postal self-
sampling, who are more likely to report high-risk 
behaviours than other community populations.22 An 
increasing proportion of chlamydia screening tests are 
being requested and commissioned via this route.22 
Management of exposed sex partners of people with 
chlamydia is challenging.23,24 We showed proof of concept 
for partner management online, but few partners were 
managed this way.
To interrupt chlamydia transmission, increased testing 
is needed in all young people, with a focus on those who 
are at high risk but are not accessing testing and engaging 
with care in traditional settings. STIs, and the groups 
who are most likely to be diagnosed with STIs, are often 
stigmatised. Assuming a person can take the first step 
online, the eSHC also provides opportunities for people 
facing barriers to accessing existing services. However, to 
achieve a reduction in the population incidence of 
chlamydia, eHealth interventions would need to be one 
of many components of a comprehensive chlamydia-
control strategy.
Panel: Public health potential of the eSexual Health Clinic system
Primary prevention
Health promotion is included at various stages of the online care pathway. This 
information is tailored towards both individuals with chlamydia and those who test 
negative, and provides opportunities to link to health-promotion and risk-reduction 
websites.
Secondary prevention
Sexually transmitted infections, including chlamydia, are frequently asymptomatic. The 
eSexual Health Clinic system has the potential to enable individuals (especially those 
with high-risk behaviours) to be tested regularly to ensure early identification and 
treatment. Partner notification is an essential component of infection control and is 
facilitated by the system, which gives individuals with chlamydia the opportunity to 
discreetly inform their partners so that they too can obtain treatment online if desired, 
breaking the chain of transmission.
Tertiary prevention
Treating people with chlamydia reduces the incidence of complications, including pelvic 
inflammatory disease, infertility, and ectopic pregnancy, which has implications for 
patients and for health-care resources.
Surveillance
The eSexual Health Clinic system collects data required for surveillance and has systems to 
ensure that people diagnosed by self-testing in the future are included in national statistics.
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The ability to provide automated surveillance 
information from both community and secondary-care 
settings, and to transfer these data to national 
surveillance systems, is essential to monitor trends, 
identify areas where local delivery needs enhancement, 
and inform public health needs. In line with the NHS 
Five Year Forward View,25 the NCSP model is based on 
local delivery, and our research shows that the eSHC is 
feasible in this context, with a range of configurations 
for health-service and screening-programme delivery. 
However, our studies also show the complexity of 
collecting online data for both surveillance and clinical 
purposes while keeping patients engaged with the 
pathway. Advances in STI self-testing diagnostics, 
which enable people to be tested and diagnosed 
completely unlinked to medical care, pose additional 
challenges for public health surveillance19 and 
prevention.
Further work is needed before wider implementation 
of the eSHC. It is not interoperable with, or directly 
embedded within, health service information-
technology systems—integration will be required for 
delivery at scale. All aspects of the intervention need 
refining, including optimisation of health-promotion 
uptake, partner-notification uptake, and provision for 
partner testing, in line with national recommendations.10 
Assess ment in randomised controlled trials26 that 
include health economic analysis to assess cost-
effectiveness is essential. Our results provide the key 
information needed for the design and delivery of such 
trials. Acceptance among health-care professionals and 
commissioners will under pin adoption into mainstream 
care. However, despite strong political support,1,27 the 
digital infrastructure and regulation of online medical 
care within the NHS remains outdated. The potential 
for eHealth to improve health outcomes will probably 
be limited if these issues are not systematically 
addressed.27
With modification, this pathway could be used in 
combination with a home self-test for other bacterial 
infections for which a standard first-line antibiotic is 
recommended, such as streptococcal pharyngitis. People 
could potentially self-test, self-diagnose, and self-manage 
remote from traditional health services. Rapid progress 
in home diagnostics for several conditions, combined 
with the ability to inter-weave targeted health promotion, 
provide opportunities for diverse eHealth interventions. 
However, the effectiveness of primary prevention 
activities, such as health promotion, delivered in this 
format would need to be assessed alongside face-to-face 
alternatives.
Our promising findings suggest that the eSHC is an 
innovative model that could address growing population 
health needs. The eSHC’s reach goes beyond sexual 
health in the UK: it could apply more broadly across 
infections and non-communicable diseases in both 
developed and developing countries.
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